Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers-Reference-Cited by-同舟云学术

Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers

Published:2008-09-07 Issue:10 Volume:8 Page:1583-1593
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Tarhini Ahmad A,Kirkwood John M

Publisher

Informa Healthcare

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.1517/14712598.8.10.1583

Reference35 articles.

1. Natural history and therapy of metastatic renal cell carcinoma

2. Cutaneous melanoma: available therapy for metastatic disease

3. Rosenberg SA. Principles of cancer management: biologic therapy. In: De Vita VT, Hellman S, Rosenberg SA, editors, Cancer principles and practice of oncology. 7th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 307-33

4. High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

5. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer;New England Journal of Medicine;2024-09-13

2. A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study;Clinical Lung Cancer;2024-05

3. A meta-analysis of the efficacy of programmed cell death 1/its ligand inhibitors plus cytotoxic T-lymphocyte-associated antigen 4 inhibitors in non-small cell lung cancer;Frontiers in Pharmacology;2024-02-05

4. Inhaled delivery of immunotherapy for treatment of lung cancer;Nanomedicine in Cancer Immunotherapy;2024

5. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON);Lung Cancer;2023-12